A phase III randomized trial of adjuvant therapy with irsogladine maleate for the patient with completely resected non-small cell lung cancer

A phase III randomized trial of adjuvant therapy with irsogladine maleate for the patient with completely resected non-small cell lung cancer - A phase III trial of adjuvant therapy with irsogladine maleate for the resected lung cancer patient

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005901

Enrollment

310

Registered

2011-07-02

Start date

2001-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

For the patient with rescted stage IA lung cancer, no adjuvant therapy is performed. For the patient with resected stage IB - IIIA, administration of tegafur-uracil for 2 years is performed. For the p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-small cell lung cancer after complete resection after lobectomy or peumonectomy after hilar and mediastinal dissection pathological stage IA - IIIA no prior treatment ECOG performance status 0-1 sufficient organ functions written informed consent

Exclusion criteria

Exclusion criteria: multiple cancer within 5 years sever organ failure past history of radiotherapy/chemotherapy women with pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
relapse-free survival	—

Countries

Japan

Contacts

Public ContactMotoyasu Sagawa

Japanese Northern East Area Thoracic Surgery Study Group (JNETS) Central study center

sagawam@kanazawa-med.ac.jp022-717-8526

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026